Oncologists need to be vigilant in Hodgkins patients with heart disease

According to a recent study, Hodgkin's lymphoma (HL) patients with pre-existing cardiovascular disease were more likely to return to the hospital for cardiac reasons than HL patients without it. This much comes as little surprise to those familiar with the complications of HL treatment and the cardiovascular system. However, the key finding appears to be that radiation therapy—specifically, radiotherapy to the chest—led to more cardiac hospitalizations (these patients had a 2.5 higher risk of such an occurrence than those without heart disease) than patients who received chemotherapy alone.

According to lead author David Hodgson, MD, of Princess Margaret Hospital Cancer Program, the study doesn't indicate that chemotherapy alone is a better treatment modality for all patients than chemotherapy plus radiation. Instead, "Oncologists need to be aware of their patients' heart health and vigilant about post-treatment monitoring and active intervention to reduce their patients' cardiac risk factors."

WHERE WAS THIS RESEARCH PUBLISHED?

Online on July 2 2010 at Blood, the journal of the American Society of Hematology.

By Ross Bonander

Citation
Sten Myrehaug, Melania Pintilie, Lingsong Yun, Michael Crump, Richard W. Tsang, Ralph M. Meyer, Jonathan Sussman, Eric Yu, and David C. Hodgson. "A population-based study of cardiac morbidity among Hodgkin lymphoma patients with pre-existing heart disease." Blood First Edition Paper, prepublished online July 1, 2010; DOI 10.1182/blood-2010-01-263764

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap